Clinical Trial Update: Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+

View source ↗

Summary

This clinical trial update shows recruiting status for regimens including isatuximab to treat relapsed/refractory multiple myeloma with 1q21+. The sponsor is IR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna | Conditions: Multiple Mieloma | Status: RECRUITING